---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-073403"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T20:47:25.255954+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025

## Summary
- FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.
- Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.
- FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.
- First FB102 vitiligo patient dosing expected shortly.

## SEC filing metadata
- accession: 0001193125-25-073403
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/0001193125-25-073403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/d876988d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-073403
- JSON: https://secwatch.observer/filing/0001193125-25-073403.json
- Plain text: https://secwatch.observer/filing/0001193125-25-073403.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.